Bleomycin

CHEMBL6067492 Phase 4 معتمد Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1415.6 g/mol

LogP

-7.5

Phase

4

A mixture of anticancer glycopeptides that damages cancer cell DNA, used to treat certain lymphomas, testicular cancers, and squamous cell carcinomas. It is also used in procedures to prevent recurrent pleural effusions. A significant risk is pulmonary toxicity, which can cause permanent lung scarring.

الوزن الجزيئي

1415,6000 g/mol

LogP

-7,50

TPSA

685,00 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O

InChI

InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1

Molecular Formula

C55H84N17O21S3+

HBD / HBA

20 / 31

الروابط القابلة للدوران

36

الذرات الثقيلة

96

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A mixture of anticancer glycopeptides that damages cancer cell DNA, used to treat certain lymphomas, testicular cancers, and squamous cell carcinomas. It is also used in procedures to prevent recurrent pleural effusions. A significant risk is pulmonary toxicity, which can cause permanent lung scarring.

Yes, Bleomycin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067492. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5360373. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Bleomycin على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C55H84N17O21S3+

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.